Cite

HARVARD Citation

    Gebbia, V. et al. (2020). Abemaciclib: safety and effectiveness of a unique cyclin-dependent kinase inhibitor. Expert opinion on drug safety. 19 (8), pp. 945-954. [Online]. 
  
Back to record